Scientific Online Resource System

Biomedical Reviews

Quo Vadis, Atherogenesis? Part 1. Smooth Muscle Cell Secretion – How Foe Becomes Friend in the Fight Against the Atherosclerotic Plaque

Peter I. Ghenev, Luigi Aloe, Antoniya R. Kisheva, Manjinder Singh, Plamen Panayotov, Marco Fiore, George N. Chaldakov

Abstract

Atherosclerosis is a chronic inflammatory disease in which exacerbation leads to myocardial infarction, stroke and/or lower limb ischemia. Phenotypic plasticity of artery smooth muscle cells (SMC) that can adapt to changes in the injured arterial microenvironment is a major determinant of atherosclerotic plaque vulnerability. Plaque instability has been associated with the ulceration or rupture of the fibrous cap composed primarily of SMC and collagen and elastin fibers, that covers the lipid core of the plaque. In this scenario, we, together with SMC, Dance round recent advances that have shed light on the relationship between inflammation, fibrosis and plaque vulnerability and stability. Specifically, we have addressed the question of how the secretory (fibrogenic) activity of SMC occurring within the plaque may become a plaque stabilizer (a friend). We describe a new paradigm shift in the cell biology of atherosclerosis that relates the inhibition of SMC matrix secretion and proliferation (the classical way for reducing plaque size) to the stimulation of these processes (the new way aimed at the plaque stabilization by increasing the thickness of its fibrous cap). Briefly, an increased secretion of matrix molecules, particularly collagen and elastin, by SMC could “shift” them from foe to friend in the fight against the vulnerable atherosclerotic plaque. Biomed Rev 2017; 28:134-138.

Keywords: atherosclerotic plaque, fibrous cap, smooth muscle cells, macrophages, phenotypic modulation, matrix proteins, inflammation, fibrosis, colchicine


Full Text


References

Ross R. Mechanisms of disease: atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115-126.

Schwartz SM, Virmani R, Rosenfeld ME. The good smooth muscle cells in atherosclerosis. Curr Atheroscler Rep 2000; 2: 422-429.

Lafont A, Libby P. The smooth muscle cell: sinner or saint in restenosis and the acute coronary syndromes? J Am Coll Cardiol 1998; 32: 283-285.

van Lammeren G, L Moll F, Borst GJ, de Kleijn DP, P M de Vries JP, Pasterkamp G, et al. Atherosclerotic plaque biomarkers: beyond the horizon of the vulnerable plaque. Curr Cardiol Rev 2011;7(1):22-27. DOI:10.2174/157340311795677680

Nurnberg ST, Cheng K, Raiesdana A, Kundu R, Miller CL, Kim LB, et al. Coronary artery disease associated transcription factor TCF21 regulates smooth muscle precursor cells that contribute to the fibrous cap. PloS Genet 2015; 11(5): e1005155. DOI: 10.1371/journal.pgen.1005155

Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, Haskins RM, et al. KLF4 dependent phenotypic modulation of SMCs plays a key role in atherosclerotic plaque pathogenesis. Nat Med 2015; 21(6): 628–637. DOI: 10.1038/nm.3866

Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res 2016; 118(4): 692–702. DOI: 10.1161/CIRCRESAHA.115.306361

Chaldakov GN, Fiore M, Ghenev PI, Stankulov IS, Angellucci F, Pavlov PS, et al. Conceptual novelties in atherogenesis: Smooth muscle cells, adventitia, and adipose tissue. Biomed Rev 2000; 11: 63-67.

Chaldakov GN, Ghenev PI. Colchicine, inflammation and fibrosis in cardiovascular disease: Merging three classical tales. Biomed Rev 2017; 28: 110-115.

Pflederer T, Marwan M, Schepis T, Ropers D, Seltmann M, Muschiol G, et al. Characterization of culprit lesions in acute coronary syndromes using coronary dualsource CT angiography. Atherosclerosis 2010; 211:437-444.DOI:10.1016/j.atherosclerosis.2010.02.001

Chaldakov GN. Antitubulins - a new therapeutic approach for atherosclerosis? Atherosclerosis 1982; 44: 385-390.

Chaldakov GN. George E. Palade lecture. Human body as a multicrine system, with special reference to cell protein secretion: From vascular smooth muscles to adipose tissue. Biomed Rev 2016; 27:VIII-XIX.

Chaldakov GN, Deyl Z, Vankov VN. Colchicine: possible new application of its antifibrotic (antisecretory) action. Physiol Bohemoslov 1987;36:1-7.

Yanev S, Fiore F, Hinev A, Ghenev PI, Hristova MG, Panayotov P, et al. From antitubulins to trackins. Biomed Rev 2016; 27: 59-67.

Solak Y, Siriopol D, Yildiz A, Yilmaz MI, Ortiz A, Covic A, et al. Colchicine in renal medicine: New virtues of an ancient friend. Blood Purif 2017;43:125-135. DOI: 10.1159/000454669.

Sansbury BE, Spite M. Resolution of acute inflammation and the role of resolvins in immunity, thrombosis and vascular biology. Circ Res 2016; 119(1): 113-130. DOI: 10.1161/CIRCRESAHA.116.307308

Martınez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C, et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc 2015;4:e002128. DOI: 10.1161/JAHA.115.002128.

Robertson S, Martinez GJ, Payet CA, Barraclough JY, Celermajer DS, Bursill C, et al. Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. Clin Sci (Lond) 2016; 130:1237-1246. DOI: 10.1042/CS20160090.

Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al; Group CPI. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012;126: 2739-2748.

Owens GK. Role of alterations in the differentiated state of smooth muscle cell in atherogenesis. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and Coronary Artery Disease. Philadelphia - New York. Lippincott-Raven, 1996; 1:401–420.

Wheatley D. On the nature of scientific discovery and progress – lessons from a career in cancer research. Biomed Rev 2017; 28:116-125.




DOI: http://dx.doi.org/10.14748/bmr.v28.4460

Refbacks

Article Tools
Email this article (Login required)
About The Authors

Peter I. Ghenev
Medical University, Varna
Bulgaria

Department of General and Clinical Pathology

Luigi Aloe
National Research Council (CNR), Rome
Italy

Institute of Cell Biology and Neurobiology

Antoniya R. Kisheva
St Marina University Hospital, Varna
Bulgaria

Clinic of Cardiology, Department of Internal Medicine

Manjinder Singh
Lovely Professional University, Phagwara, Punjab
India

School of Pharmaceutical Sciences

Plamen Panayotov
St Marina University Hospital, Varna
Bulgaria

Department of Cardiac Surgery

Marco Fiore
National Research Council (CNR), Rome
Italy

Institute of Cell Biology and Neurobiology

George N. Chaldakov
Medical University, Varna
Bulgaria

Department of Anatomy and Cell Biology

Font Size


|